<p><strong>微創醫療科技公司</strong> (HKG:853) 的股東在看到股價在上個季度下跌 17% 後，可能會感到擔憂。但這並不改變過去一年回報非常強勁的事實。我們很高興地報告，在此期間股價上漲了 119%。因此，從這個角度來看最近的價格下跌是很重要的。真正的問題是，公司的發展方向是否正確。</p>
<p>由於該股票在過去一週內為其市值增加了 18 億港元，讓我們看看基礎業績是否推動了長期回報。</p>
<p>這項技術可能會取代計算機：發現 20 只正在努力使量子計算成為現實的股票。</p>
<p>微創醫療目前尚未盈利，因此大多數分析師會關注收入增長，以瞭解基礎業務的增長速度。當一家公司沒有盈利時，我們通常希望看到良好的收入增長。一些公司願意推遲盈利以更快地增長收入，但在這種情況下，人們希望看到良好的收入增長來彌補缺乏盈利。</p>
<p>微創醫療實際上在過去一年中收入減少了 0.7%。我們對股價在過去一年中上漲 119% 感到有些驚訝。這表明市場並不總是關注報告的數字。無論如何，收入下降很可能已經被市場定價。</p>
<p>您可以在下面看到收益和收入隨時間的變化（點擊圖片可以發現確切的數值）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1768089747164?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1768089747164"/></p>
<p>SEHK:853 收益和收入增長 2026 年 1 月 11 日</p>
<p>我們喜歡看到內部人士在過去十二個月中購買股票。儘管如此，未來的收益對當前股東是否賺錢將更為重要。因此，我們建議查看這份 <strong>免費</strong> 報告，顯示共識預測。</p>
<h2>不同的視角</h2>
<p>很高興看到微創醫療的股東在過去一年中獲得了 119% 的總股東回報。毫無疑問，這些近期回報遠好於過去五年每年 12% 的總股東回報損失。長期損失讓我們感到謹慎，但短期的總股東回報增長無疑暗示着更光明的未來。喜歡賺錢的投資者通常會關注內部人士的購買情況，例如支付的價格和購買的總金額。您可以通過點擊此鏈接瞭解微創醫療的內部人士購買情況。</p>
<p>微創醫療並不是唯一一家內部人士在購買的股票。因此，看看這份 <strong>免費</strong> 的小型公司名單，這些公司在吸引人的估值下被內部人士購買。</p>
<p><em>請注意，本文中引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報。</em></p>

微創醫療

<p>微創醫療（HKG:853）在過去一年中為股東帶來了令人矚目的 119% 的回報，儘管在最近一個季度股價下跌了 17%。該股票在過去一週上漲了 8.6%，為其市值增加了 18 億港元。然而，公司報告的收入下降了 0.7%，這引發了對其長期增長潛力的質疑。過去一年內部人士的增持是一個積極信號，但未來的盈利將對維持股東回報至關重要。總體而言，短期收益與過去五年每年 12% 的長期總回報損失形成了鮮明對比</p>

<p><strong>MicroPort Scientific Corporation</strong> (HKG:853) shareholders might be concerned after seeing the share price drop 17% in the last quarter. But that doesn't change the fact that the returns over the last year have been very strong. We're very pleased to report the share price shot up 119% in that time. So it is important to view the recent reduction in price through that lense. The real question is whether the business is trending in the right direction.</p>
<div class="lb-trans"><p><strong>微創醫療科技公司</strong> (HKG:853) 的股東在看到股價在上個季度下跌 17% 後，可能會感到擔憂。但這並不改變過去一年回報非常強勁的事實。我們很高興地報告，在此期間股價上漲了 119%。因此，從這個角度來看最近的價格下跌是很重要的。真正的問題是，公司的發展方向是否正確。</p>
</div><p>Since the stock has added HK$1.8b to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.</p>
<div class="lb-trans"><p>由於該股票在過去一週內為其市值增加了 18 億港元，讓我們看看基礎業績是否推動了長期回報。</p>
</div><p>This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.</p>
<div class="lb-trans"><p>這項技術可能會取代計算機：發現 20 只正在努力使量子計算成為現實的股票。</p>
</div><p>MicroPort Scientific isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally hope to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.</p>
<div class="lb-trans"><p>微創醫療目前尚未盈利，因此大多數分析師會關注收入增長，以瞭解基礎業務的增長速度。當一家公司沒有盈利時，我們通常希望看到良好的收入增長。一些公司願意推遲盈利以更快地增長收入，但在這種情況下，人們希望看到良好的收入增長來彌補缺乏盈利。</p>
</div><p>MicroPort Scientific actually shrunk its revenue over the last year, with a reduction of 0.7%. We're a little surprised to see the share price pop 119% in the last year. It just goes to show the market doesn't always pay attention to the reported numbers. It's quite likely the revenue fall was already priced in, anyway.</p>
<div class="lb-trans"><p>微創醫療實際上在過去一年中收入減少了 0.7%。我們對股價在過去一年中上漲 119% 感到有些驚訝。這表明市場並不總是關注報告的數字。無論如何，收入下降很可能已經被市場定價。</p>
</div><p>You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).</p>
<div class="lb-trans"><p>您可以在下面看到收益和收入隨時間的變化（點擊圖片可以發現確切的數值）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1768089747164" alt="" original-src="https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1768089747164"/></p>
<p>SEHK:853 Earnings and Revenue Growth January 11th 2026</p>
<div class="lb-trans"><p>SEHK:853 收益和收入增長 2026 年 1 月 11 日</p>
</div><p>We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. So we recommend checking out this <strong>free</strong> report showing consensus forecasts</p>
<div class="lb-trans"><p>我們喜歡看到內部人士在過去十二個月中購買股票。儘管如此，未來的收益對當前股東是否賺錢將更為重要。因此，我們建議查看這份 <strong>免費</strong> 報告，顯示共識預測。</p>
</div><h2>A Different Perspective</h2>
<div class="lb-trans"><h2>不同的視角</h2>
</div><p>It's nice to see that MicroPort Scientific shareholders have received a total shareholder return of 119% over the last year. There's no doubt those recent returns are much better than the TSR loss of 12% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. Investors who like to make money usually check up on insider purchases, such as the price paid, and total amount bought. You can find out about the insider purchases of MicroPort Scientific by clicking this link.</p>
<div class="lb-trans"><p>很高興看到微創醫療的股東在過去一年中獲得了 119% 的總股東回報。毫無疑問，這些近期回報遠好於過去五年每年 12% 的總股東回報損失。長期損失讓我們感到謹慎，但短期的總股東回報增長無疑暗示着更光明的未來。喜歡賺錢的投資者通常會關注內部人士的購買情況，例如支付的價格和購買的總金額。您可以通過點擊此鏈接瞭解微創醫療的內部人士購買情況。</p>
</div><p>MicroPort Scientific is not the only stock insiders are buying. So take a peek at this <strong>free</strong> list of small cap companies at attractive valuations which insiders have been buying.</p>
<div class="lb-trans"><p>微創醫療並不是唯一一家內部人士在購買的股票。因此，看看這份 <strong>免費</strong> 的小型公司名單，這些公司在吸引人的估值下被內部人士購買。</p>
</div><p><em>Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.</em></p>
<div class="lb-trans"><p><em>請注意，本文中引用的市場回報反映了目前在香港交易所交易的股票的市場加權平均回報。</em></p>
</div>

微創醫療（HKG:853）在過去一年中為股東帶來了令人矚目的 119% 回報，僅在上週就上漲了 8.6%